KORSCH introduces next-generation mid-range tablet press
X 3 Tablet Press incorporates production capabilities and versatility traditionally limited to large-scale production machines.
KORSCH is introducing a mid-range tablet press incorporating innovative features previously available only on large production machines.
The new X 3 Tablet Press is a single-sided rotary press that redefines this market segment, with flexible technology and a new approach to architectural and ergonomic design.
Suitable for product development, scale-up, clinical production, mid-range production and continuous manufacturing, the next-generation X 3 Tablet Press is available in two models. The X 3 SFP is a dedicated single-layer press capable of 266,400 tablets/hour, whereas the X 3 MFP offers flexible single-layer (266,400 tablets/hour) and bi-layer (133,200 tablets/hour) production capability.
The X 3 incorporates a flexible manufacturing experience atypical for its size, with an integrated electrical cabinet, torque drive, fully sealed design, and unsurpassed accessibility for cleaning, changeovers and maintenance.
Installation options include a conventional in-room layout, through-the-wall mounting, and a portable equipment platform. The X 3 offers a range of product containment configurations, including OEB 3, as well as OEB 4/5 with full wash-in-place and high-containment execution.
In addition, the X 3's exchangeable turret technology allows for an extremely fast transition between products, and the ability to produce a tablet of any size and shape.
For mid-range manufacturing, the X 3 offers a long filling length and large, variable-speed power feeder for precision die filling at extremely high speeds. For changeovers, superior compression zone access, smooth surfaces, and minimal fast change parts yield an expedited process for maximized machine uptime.
The unique KORSCH machine structure provides excellent visibility and unlimited access to the compression zone for streamlined changeover and turret exchange. It is a fully sealed machine with no heat transfer to the compression zone of the press, or to the compression room. This closed design also eliminates potential contamination in the machine base or electrical cabinet, and further expedites the changeover process.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance